CALGARY — November 13, 2026 -- The Japan Patent Office (JPO) has issued a Decision to Grant for XORTX Therapeutics' application covering six claims on xanthine oxidase inhibitor compositions, including oxypurinol, for acute kidney injury linked to viral infection. Once registered, it will be the Nasdaq-listed company's first Japanese patent for its xanthine oxidase inhibitor programs and is expected to run to March 15, 2041, exactly 21 years after its March 15, 2020 U.S. priority filing, by FairsOnline's calculation.
The patent is not yet in force. It issues only after XORTX pays the registration fee and the JPO registers it. The company did not say when it expects registration. The expiry date is subject to annuity fees and excludes any patent term extension that may become available.
JPO allows six claims on inhibitor compositions for viral kidney injury
Japanese Application No. 2022-556140, titled "Compositions, Formulations, and Containers," is the national phase of International Application PCT/IB2021/000238. It claims priority to U.S. Provisional Application No. 62/989,879. The allowed claims cover pharmaceutical compositions for treating or preventing acute kidney injury and other health consequences of viral infection.
The company says therapeutic uses are generally protected through composition claims under Japanese patent practice. It supports the XRx-101 program for acute kidney injury and other acute organ injury tied to respiratory virus infections.
Japan grant is one of seven granted or allowed XORTX patents
XORTX reports seven granted or allowed patents and 14 pending applications in the United States, Europe and Japan. The Japanese decision therefore accounts for about 14% of the granted or allowed group (1 of 7). The 14 pending applications make up about two-thirds of the 21 granted, allowed and pending filings (14 of 21). The company also holds roughly 30 patents acquired with its VB4-P5 renal anti-fibrotic program.
Co-CEO Allen Davidoff says Japan is one of the world's largest pharmaceutical markets. He says the patent broadens the company's options as it evaluates partnering for programs beyond its lead gout candidate, XRx-026.
XORTX has signed no partner for XRx-101
The company states it has no partnering, licensing or other agreement with any party on XRx-101. It says there is no assurance it will conclude one on acceptable terms, or at all. XRx-101 is not the company's lead program.
XORTX lists as risks that the registered patent could be challenged, narrowed or invalidated in post-grant opposition or invalidation proceedings before the JPO, and that no patent term extension may be available.